Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Comment by Pausinion Sep 05, 2021 4:52pm
289 Views
Post# 33815853

RE:RE:RE:RE:Meeting's Over ! Now play your CARDS

RE:RE:RE:RE:Meeting's Over ! Now play your CARDS
@pennyqueen summary comments for week ending Sept 3;
 
**Xortx** – Great week for Xortx!  The shareholders approved the rollback and funding for the Nasdaq IPO.  Bob McWhirter put the company out as his top pick and beginning Tuesday the company can start promoting itself and letting out good news.  They have been barred from promotion by the SEC as is standard with uplisting requirements. TSX uplist appears to be approved and should happen at any time (but I’ve been saying this for two weeks).  I expect the Uplisting to the DAQ to be at the end of September or first week of October.
<< Previous
Bullboard Posts
Next >>